Pharma BD Deal Intelligence
Platform access to AI antibody design; discovery-stage optionality
Full analysis, sources & comparables →Chai Discovery, an AI drug-design company, entered a collaboration with Novartis to apply its latest AI models — including Chai-3 — to therapeutic antibody discovery across multiple biological targets and programs. The agreement follows more than a year of technical engagement in which Novartis had early access to Chai's next-generation protein-folding model. Chai-3 materially improves target success rates and binding affinity versus its predecessor. Financial terms and specific disease areas were not disclosed. The pact adds Novartis to Chai's pharma customer base alongside Pfizer and Eli Lilly.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Chai Discovery, Inc. (this deal) | 2026 | — | 59 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2026 deals · Novartis AG deals · Multiple (undisclosed) deals